Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer
Brian D. Cortese(University of Pennsylvania), Ruchika Talwar(Vanderbilt University Medical Center), Kelvin A. Moses(Bristol-Myers Squibb (Germany)), Bashir Al Hussein Al Awamlh(Cornell University), Daniel A. Barocas(Vanderbilt University Medical Center), Kristen R. Scarpato(Vanderbilt University Medical Center), Amy N. Luckenbaugh(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center), Sam S. Chang(Vanderbilt University), Stacie B. Dusetzina(University of North Carolina at Chapel Hill)
Cited by 9
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592